Changeflow GovPing Pharma & Drug Safety ATTOCONEXA Trademark Application Published for ...
Routine Notice Added Consultation

ATTOCONEXA Trademark Application Published for Opposition

Favicon for changeflow.com ChangeBridge: Trademarks - Pharmaceuticals (Class 005)
Published March 26th, 2026
Detected March 27th, 2026
Email

Summary

The USPTO has published the trademark application for ATTOCONEXA, filed by a pharmaceutical entity. This publication initiates a period for opposition before the trademark can be officially registered.

What changed

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'ATTOCONEXA' (TM79444741) for opposition. The application covers a broad range of research preparations, reagents, and kits for medical, veterinary, and scientific research, including antibodies, nucleic acid probes, diagnostic aptamers, and histological dyes, primarily intended for pharmaceutical and biotechnology applications.

This publication marks a procedural step in the trademark registration process, allowing third parties to file oppositions if they believe the mark infringes on their existing rights. Companies involved in similar research or diagnostic product areas should monitor this application for potential conflicts. The effective date of publication is March 26, 2026, with a filing date of November 19, 2025.

What to do next

  1. Monitor trademark opposition period for ATTOCONEXA application (TM79444741).

Source document (simplified)

← USPTO Trademark Applications

ATTOCONEXA

Published for Opposition TM79444741 Kind: published Mar 26, 2026

Abstract

Research preparations, namely antibodies or nucleic acid probes, for the investigation of disease models; preparations for medical and veterinary research; reagents containing primary antibodies for research use; chemical reagents and medical preparations for research purposes; clinical research reagents; chemical reagents for medical or veterinary research purposes, namely reagents for immuno-histochemistry detection and in situ-hybridisation detection; in situ-hybridisation probes for medical research purposes; epitope retrieval solutions for medical research purposes; enzymes and enzyme preparations for medical research purposes; histological dye and stain solutions for medical research purposes; dewaxing and wash buffers used with the aforementioned preparations; fluorescent dyes and fluorescent labels for diagnostic use; assay reagents for diagnostic use; aptamers for diagnostic use; affinity reagents for diagnostic use; supramolecular host-guest systems for diagnostic use; reagents containing primary antibodies, aptamers, affimers, or other affinity reagents, nucleic acid probes, fluorescent dyes, fluorescent labels, non-optically detectable labels, blocking agents, inactivation agents for diagnostic use; kits comprising a combination of any of the aforesaid research reagents, preparations for medical and veterinary research, clinical research reagents, in situ-hybridisation probes, epitope retrieval solutions, enzymes and enzyme preparations, histological dyes and stain solutions, dewaxing and wash buffers, fluorescent dyes and fluorescent labels, assay reagents, aptamers, affinity reagents, supramolecular host-guest systems, reagents containing primary antibodies, affimers, or other affinity reagents, nucleic acid probes, non-optically detectable labels, blocking agents and inactivation agents, all for diagnostic and medical research purposes.; Chemicals for use in industry and science; chemical reagents for non-medical purposes; reagents for research purposes; research reagents and preparations, except for medical or veterinary use; research preparations used in science; chemical reagents and diagnostic preparations for use in research laboratories and for use in industry; fluorescent dyes and fluorescent labels for applications in industry and science; assay reagents for use in research, quality control, diagnostic use; aptamers for use in research, quality control; affinity reagents for use in research or quality control; supramolecular host-guest systems for use in research or quality control; reagents containing primary antibodies, aptamers, affimers, or other affinity reagents, nucleic acid probes, fluorescent dyes, fluorescent labels, non-optically detectable labels, blocking agents, inactivation agents for research use; kits comprising a combination of any of the aforesaid chemical reagents, research reagents and preparations, assay reagents, affinity reagents, supramolecular host-guest systems, nucleic acid probes, fluorescent dyes, fluorescent labels, non-optically detectable labels, blocking agents and inactivation agents, all for industrial, scientific and research use.

Filing Date

2025-11-19

View original document →

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor
Document ID
TM79444741

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Trademark Registration
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Trademarks - Pharmaceuticals (Class 005) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.